Skip to main content

Table 4 The details of the druggable binding site, their docking score and binding energy, least complex energy and the main interaction showed amino acid residues at the binding site

From: Docking and dynamic simulation study of Crizotinib and Temozolomide drug with Glioblastoma and NSCLC target to identify better efficacy of the drug

Protein name and drug name

Type of docking

Docking score

Binding energy (kcal/mol)

Complex energy (kcal/mol)

Interacting residues

2WGJ

PDB(P6)

139.105

− 44.14

− 11,179.9569

MET1160,PRO1158,ASP1164

DRUG-CRIZOTINIB

RC(S2,P4)

137.169

− 15.3749

− 11,155.5712

ASP1164,PRO1158,MET1160

DIRECT(P2)

106.855

114.7614

− 11,028.5560

ASP1164,PRO1158,MET1160

MOTIF

3ZBF

PDB(P6)

113.349

− 106.9428

− 11,509.9762

ASP2033,GLU2027,MET2029

DRUG-CRIZOTINIB

RC(S1,P4)

92.346

62.0108

− 11,400.4896

GLU2027,MET2029

DIRECT(P3)

98.9302

− 20.1590

− 11,473.5427

GLU2027,MET2029

 

MOTIF(P1)

114.545

− 112.0438

− 11,514.2552

ASP2033,GLU2027, MET2029

2XP2

PDB(P10)

111.801

− 135.9488

− 11,600.2395

GLU1197, MET1199

DRUG-CRIZOTINIB

RC(S1, P8)

108.615

− 189.7012

− 11,666.7948

GLU1197, MET1199

DIRECT(P1)

118.508

− 193.8604

− 11,648.2048

GLU1197,MET1199, ASP1203, SER1206

MOTIF(P9)

107.35

− 176.1679

− 11,656.9972

GLU1197,MET1199,ASP1203